19.11.2020 08:22
BioVersys has entered clinical development with the start of Phase 1 testing of BV100, a novel therapy designed for the treatment of severe hospital infections caused by carbapenem resistant acinetobacter baumannii. By dosing healthy volunteers, the study will evaluate the safety, tolerability, and pharmacokinetics of the therapy.